

Prof. Yaakov Nahmias

Founder & CSO, Tissue Dynamics

Founder & CSO, Future Meat Technologies

Director, Grass Center for Bioengineering

The Hebrew University of Jerusalem

Prof. Yaakov “Koby” Nahmias is an Israeli bioengineer and innovator, whose technological breakthroughs ranged from the first 3D printing of human cells, to human-on-chip technologies and cost-effective manufacturing of cultured meat. Nahmias is the *Magna Cum Laude* graduate of the Technion, Israel Institute of Technology. He did his PhD at the University of Minnesota and his postdoctoral training at Massachusetts General Hospital. Nahmias served as faculty member at Harvard Medical School, receiving a National Institute of Health (NIH) Career Award in 2006. He was recruited by the Hebrew University in 2010 to found and direct the Center for Bioengineering. His leadership was instrumental in raising the center’s \$5M endowment and recruiting several core faculty that raised over \$20M over the past five years.



Nahmias won two prestigious European Research Council (ERC) grants raising over \$7M in independent research funding. In recognition of his achievements, Nahmias won the Golda Meir Lectureship Award in 2011, the prestigious Rappaport Prize in Biomedical Research in 2014 and the Kaye Innovation Award in 2018. In 2017 he became the first scientist outside Britain to win the Rosetrees Trust Interdisciplinary Prize for his pioneering work on liver-on-chip. Nahmias is a fellow of both the prestigious American Institute for Medical and Biological Engineering (AIMBE) and the British Royal Society of Medicine (RSM). He is an editorial board member of the Annual Reviews for Biomedical Engineering, and a long-standing member of the European Research Council LS9 Biotechnology committee.

Nahmias is the co-founder of BioDesign-Israel, a multidisciplinary program in medical device innovation sponsored by Boston Scientific. The program educated over 120 fellows, raising \$3M in investment and 10 startup companies including [Guide In Medical](#), that received FDA approval in Jan. 2018, [CardioVia](#) and [VenoVision](#). Nahmias is the founder and CSO of two biotechnology startups, including [Tissue Dynamics](#) that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded [Future Meat Technologies](#) focusing on the cost-effective production of cultured meat.